TL;DR — Ginkgo biloba standardized extract (EGb 761: 24% flavone glycosides, 6% terpene lactones) is a vasodilator + antioxidant with real, large RCT evidence for cognitive function in dementia (Le Bars 1997, PMID 9343463) and mixed evidence for prevention in healthy adults (GEM trial 2008, PMID 18544724 — negative for AD prevention). Standard dose 120–240 mg/day EGb 761; expect signal at 12+ weeks; discontinue 2 weeks before surgery due to platelet effects.
What ginkgo biloba does (and why it matters)
Ginkgo biloba is the world's oldest living tree species (~270 million years). Its leaf extract contains two active fractions: flavone glycosides (quercetin, kaempferol, isorhamnetin — antioxidants) and terpene trilactones (ginkgolides A/B/C, bilobalide — PAF antagonists + neuroprotectants).
The clinical rationale for aging: cerebral perfusion declines ~10% per decade after age 30. Ginkgolides antagonize platelet-activating factor (PAF), reducing platelet aggregation and improving microcirculation. Bilobalide protects mitochondrial complexes I and III from ischemia-reperfusion damage.
Primary hallmarks targeted: Altered intercellular communication (vascular/cognitive signaling) · Mitochondrial dysfunction · Chronic inflammation
Le Bars et al. (1997, PMID 9343463) randomized 309 mild-to-moderate AD/multi-infarct dementia patients to EGb 761 120 mg/day for 52 weeks — ADAS-Cog improved 1.4 points vs placebo (clinically small but real). Ihl et al. (2011, PMID 21129580) meta-analysis of 9 EGb 761 dementia RCTs (n=2,561) confirmed cognitive and behavioral benefits at 240 mg/day. The GEM trial (DeKosky 2008, PMID 19017911) — 3,069 healthy adults ≥75, EGb 761 240 mg/day for 6+ years — was negative for preventing incident dementia.
Mechanism
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| PAF antagonism | Ginkgolide B binds PAF receptor → ↓ platelet aggregation | Communication |
| Cerebral blood flow | Vasodilation via NO + endothelial function | Communication |
| Mitochondrial protection | Bilobalide preserves Complex I/III in ischemia | Mitochondrial dysfunction |
| Antioxidant | Flavone glycosides quench ROS | Inflammation |
| MAO-B inhibition | Mild, contributes to dopaminergic effects | Communication |
When ginkgo is worth your money
Ginkgo earns a place in your stack when two or more apply:
- Age 65+ with subjective memory complaint OR mild cognitive impairment diagnosed
- History of intermittent claudication or vascular cognitive symptoms
- Tinnitus with vascular component (peripheral, not pulsatile)
- Building a stack around cognitive support and vascular optimization
Skip or defer if you're healthy under 60 with no cognitive complaint (GEM was negative for prevention), on any anticoagulant, or scheduling surgery within 2 weeks.
Evidence summary
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Le Bars 1997 (PMID 9343463) | RCT (EGb 761) | 309 | 52 wk | ↑ ADAS-Cog 1.4 in AD/MID | B |
| Ihl 2011 meta (PMID 21129580) | Meta-analysis | 2561 | 12–26 wk | ↑ Cognition, behavioral symptoms at 240 mg | B |
| GEM 2008 (PMID 19017911) | RCT (prevention) | 3069 | 6+ yr | No prevention of dementia in healthy elderly | A (neg) |
| Amieva 2013 (PMID 24086148) | RCT | 2854 | 5 yr | No slowing of cognitive decline in memory-complaint elderly | B |
| Herrschaft 2012 (PMID 22591951) | RCT | 410 | 24 wk | ↑ SKT, NPI in AD/vascular dementia at 240 mg | B |
← Swipe for more columns →
Consensus: Tier B for treating established cognitive impairment (AD, vascular dementia, MCI) at 240 mg/day EGb 761. Tier A NEGATIVE for preventing dementia in healthy elderly — the GEM trial is clear on this. Longevity outcome data does not exist.
Where ginkgo disappoints
- Prevention in healthy adults. GEM and Amieva both failed. Do not take ginkgo hoping to prevent dementia if you have no cognitive symptoms. - Non-EGb 761 products. The vast majority of RCT evidence uses the specific Schwabe EGb 761 extract (24% glycosides, 6% terpenes). Generic ginkgo may not be equivalent — many contain <5% actives and no standardization. - The bleeding-risk story is real. Case reports of spontaneous subdural hematomas exist. Ginkgolides antagonize PAF; effect is small alone but additive with aspirin, NSAIDs, or SSRIs.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 120–240 mg/day standardized EGb 761 | 240 mg for dementia-range benefit |
| Timing | Divided BID with meals | Peak plasma 2–3h |
| Duration | 12+ weeks minimum for cognitive assessment | RCTs run 12–52 wk |
| Standardization | 24% flavone glycosides + 6% terpene lactones | Verify on label |
Monitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Cognitive score (MoCA / MMSE) | Stable or improving | Baseline + 6 mo | If declining, ginkgo alone won't reverse — escalate care |
| Platelet function / bleeding signs | Normal | Ongoing self-monitor | Bruising / prolonged bleeding → stop, MD review |
| Blood pressure | Unchanged | Monthly | Ginkgo can mildly ↓ BP; adjust antihypertensives if needed |
← Swipe for more columns →
Safety, red flags, and contraindications
- Generally well tolerated; GI upset, headache (~3%) at trial doses.
- Discontinue 2 weeks before any surgery or dental extraction.
- Watch for the bleeding-risk stacking pattern — ginkgo + fish oil + garlic + vitamin E + NSAID is a real bleeding risk.
Do not self-start without clearance
- On warfarin, DOACs, or antiplatelet drugs — additive bleeding risk; case reports of hematomas.
- Seizure disorder — rare pro-convulsant reports at very high doses (>480 mg).
- Scheduled surgery — stop 2 weeks before.
- Pregnancy — insufficient safety data.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Bacopa monnieri | Complementary — bacopa builds long-term memory consolidation, ginkgo improves acute cerebral flow | Cognitive stack |
| Panax ginseng | The GINPI trial combined them; effects were additive | Cognitive stack |
| Cocoa flavanols | Both improve endothelial NO / cerebral perfusion | Vascular stack |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| Warfarin / DOACs | Additive bleeding | Do not combine without physician management + INR monitoring |
| SSRIs (fluoxetine, paroxetine) | Platelet SERT + PAF antagonism → bleeding risk | Discuss with prescriber |
| High-dose vitamin E (>400 IU) + garlic + fish oil | Bleeding-time additive effect | Stagger or drop one |
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.